Contact Dermatitis - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Contact Dermatitis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Contact dermatitis - Pipeline Review, H2 2015', provides an overview of the Contact dermatitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Contact dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contact dermatitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Contact dermatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Contact dermatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Contact dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Contact dermatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Contact dermatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Contact dermatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Contact Dermatitis Overview 7
Therapeutics Development 8
Pipeline Products for Contact Dermatitis - Overview 8
Pipeline Products for Contact Dermatitis - Comparative Analysis 9
Contact Dermatitis - Therapeutics under Development by Companies 10
Contact Dermatitis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Contact Dermatitis - Products under Development by Companies 13
Contact Dermatitis - Companies Involved in Therapeutics Development 14
Accolade Pharma LLC 14
Aldeyra Therapeutics, Inc. 15
Anacor Pharmaceuticals, Inc. 16
AskAt Inc. 17
Brickell Biotech, Inc. 18
Hapten Sciences, Inc. 19
ILiAD Biotechnologies, LLC 20
Marinomed Biotechnologie GmbH 21
R-Tech Ueno, Ltd. 22
Signum Dermalogix, Inc 23
Contact Dermatitis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
AAT-008 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AN-3485 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
BBI-2111 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
beta-escin - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
grapiprant - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
HPT-721 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NS-2 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
pertussis [strain BPZE1] vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
RTU-1096 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
SIG-1322 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Zafi-1 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Contact Dermatitis - Recent Pipeline Updates 47
Contact Dermatitis - Dormant Projects 51
Contact Dermatitis - Dormant Projects 51
Contact Dermatitis - Discontinued Products 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables

Number of Products under Development for Contact Dermatitis, H2 2015 8
Number of Products under Development for Contact Dermatitis - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Contact Dermatitis - Pipeline by Accolade Pharma LLC, H2 2015 14
Contact Dermatitis - Pipeline by Aldeyra Therapeutics, Inc., H2 2015 15
Contact Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2015 16
Contact Dermatitis - Pipeline by AskAt Inc., H2 2015 17
Contact Dermatitis - Pipeline by Brickell Biotech, Inc., H2 2015 18
Contact Dermatitis - Pipeline by Hapten Sciences, Inc., H2 2015 19
Contact Dermatitis - Pipeline by ILiAD Biotechnologies, LLC, H2 2015 20
Contact Dermatitis - Pipeline by Marinomed Biotechnologie GmbH, H2 2015 21
Contact Dermatitis - Pipeline by R-Tech Ueno, Ltd., H2 2015 22
Contact Dermatitis - Pipeline by Signum Dermalogix, Inc, H2 2015 23
Assessment by Monotherapy Products, H2 2015 24
Number of Products by Stage and Target, H2 2015 26
Number of Products by Stage and Mechanism of Action, H2 2015 28
Number of Products by Stage and Route of Administration, H2 2015 30
Number of Products by Stage and Molecule Type, H2 2015 32
Contact Dermatitis Therapeutics - Recent Pipeline Updates, H2 2015 47
Contact Dermatitis - Dormant Projects, H2 2015 51
Contact Dermatitis - Discontinued Products, H2 2015 52